美国的微信圈子今早流传一个视频，吉利德公司CEO在内部会议上回答员工提问，第一次回应武汉病毒所申请Remdesivir (瑞德西韦 ) 治疗新冠病毒的专利问题。
关于这个救命药，我前两天写了一篇：武汉肺炎特效药即将问世？满载地球人希望的 Remdesivir。至于武汉病毒所1月21号，封城之前，”抢注”此药在中国的使用专利，我推荐丁香园的一篇公众号文章，从医学和法理的角度，分析得比较专业和全面。
对这个问题我不想过多评论，谁是谁非大家都不是傻子，心里很清楚。
下面是我整理和翻译的中英文对话：
员工：最近有媒体报道，中国的武汉病毒所，和军事科学院一起，申请了瑞德西韦药品的专利。很显然，在抗击疫情，治病救人和保护知识产权之间有一个微妙的平衡。我的问题是，这个有点敏感，但是我想知道吉利德公司针对这个（专利）申请有什么反应。如果中国专利局批准了这项专利，吉利德的立场是什么。
Gilead Employee: Recently there was some reporting that China’s Wuhan Virology Institute, together with the Chinese Military Academy, they applied for the patent of remdesivir. So obviously this is a delicate balance between fighting the epidemic and saving lives, vs IP protection. Question, so this is little bit…probably delicate, but I do want to know what is Gilead’s reaction to this application and what’s Gileard’s stance if China’s IP authority approves this (patent) application. How are we gonna continue to manage the control of remdesivir development, and also you know, retaining the right to help fight the epidemic.
吉利德CEO：非常感谢。 这是一个极其相关的问题。显而易见，这个事情一夜之间才冒出来，就像所有跟remdesivir有关的事情一样，我们正在竭尽所能快速行动。 我想对你和所有在座各位传达的信息是，这件事，不会对我们为全球健康所做的努力产生任何影响。
Gilead CEO: Thank you so much. It’s a very relevant question. Obviously it just came out overnight, and like everything around remdesivir, you know, we’re moving as quickly as we can. I think my message to you and everybody, is that has no impact upon what we’re gonna do for global health.
我只想在这里非常清楚，毫不含糊地强调，我们的责任是患者。 我们的责任是，第一，寻找并推行合适的临床试验，以确定这款药物是否会对患者有效，然后我们将以科学和临床证据为基础开展下一步行动，同时，如果真有效的话，加快生产，以便我们能够把这种药物提供给全球尽可能多的患者。
I just want to be tremendously clear here, that our responsibility is the patients. And our responsibility is that No. 1, pursue the right clinical programs to determine whether or not this medicine has impact with patients or not, then we’ll be driven by the science, by the clinical evidence, and at the same time, ramping our production up in the event that it does, that we can get this medicine to as many patients around the globe.
专利不是我们现在关注的首要问题。我要说的是，跟我们这里负责专利的同事谈过，就像吉利德公司的任何药品一样，我们在世界各地都拥有瑞德西韦的专利，不仅包括该药的化合物，还包括其包括冠状病毒在内的所有用途。 我们不会陷入专利纠纷，我们总能找到帮助患者的方法。 当然，在此过程中我们也会同时保护我们的知识产权，但首先考虑的是患者。
And the patent is not at the forefront of our line. I will say that as I checked with our patent colleagues, as we were with any medicine at Gilead, we have patents on remdesivir, not only for the compound, but also for all of its uses including coronavirus, in regions around the world. We will not get into a patent dispute, we will find a way to help patients. And of course we’ll protect our intellectual property as a separate step of the process, but patients first.
至于视频，我不知道出处，也不知道原作者是谁，所以暂时不贴了。如果哪位读者认识作者，愿意授权，请尽快告诉我，我会贴在这里。现在放上音频（因为原视频上有很多员工的正面照）：
如果我记录的英文对话有遗漏，请大家补充（leave a reply below）。
欢迎大家转发这篇文章，真相和真药一样重要。
